CIT

CIT has opened its new U.S. subsidiary, CITox, Inc. based in Boston, MA, and Bernard Galat has been appointed vice president of business development, North America to spearhead the company’s expansion of U.S. activities. The U.S. represents 15% of CIT’s current sales and the company plans to increase this to 30% in the next three to five years.

“We are excited to make this significant investment which affirms CIT’s commitment to our North American clients and provides the opportunity to deliver an even higher quality of service as we increase our market share,” said Sophie Baratte, chief executive officer of CIT.

“CIT is also pleased to introduce Bernard Galat and announce this key appointment as a further indication of our continued customer centric growth,” said Ms. Baratte. “Bernard has a strong background in serving customer needs and developing high value relationships. The additional benefits derived from his knowledge and experience in driving market expansion and revenues will be integral to the growth of CIT.”

Prior to joining the company, Mr. Galat held senior sales and marketing positions with Xceleron Inc., Parexel International and Carestat, Inc. Previously, he served as vice president of sales, marketing and clinical applications for Ultracision, Inc., where he recruited, trained and managed a global sales force and led teams to establish priorities for new product development.